Wright W Nichols

List of Publications by Year
in descending order

41 papers	1,838 citations	279798 23 h-index	289244 40 g-index
41 all docs	41 docs citations	41 times ranked	1442 citing authors

#	Article	IF	Citations
1	The primary pharmacology of ceftazidime/avibactam: in vitro translational biology. Journal of Antimicrobial Chemotherapy, 2022, 77, 2321-2340.	3.0	4
2	The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD). Journal of Antimicrobial Chemotherapy, 2022, 77, 2341-2352.	3.0	9
3	Evaluation of the post-antibiotic effect in vivo for the combination of a Î²-lactam antibiotic and a Î²-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections. Journal of Chemotherapy, 2021, 33, 400-408.	1.5	1
4	Selecting the dosage of ceftazidimeâ€“avibactam in the perfect storm of nosocomial pneumonia. European Journal of Clinical Pharmacology, 2020, 76, 349-361.	1.9	9
5	Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	51
6	A model-based analysis of pharmacokineticâ€“pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa. Clinical Microbiology and Infection, 2019, 25, 904.e9-904.e16.	6.0	14
7	Avibactam Pharmacokinetic/Pharmacodynamic Targets. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	62
8	A mathematical model-based analysis of the timeâ€“kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 1295-1304.	3.0	24
9	Efficacy of ceftazidimeâ€“avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying bla_{KPC-2}. Journal of Chemotherapy, 2018, 30, 95-100.	1.5	5
10	Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2018, 73, 3336-3345.	3.0	26
11	Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
12	Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. International Journal of Antimicrobial Agents, 2018, 52, 697-701.	2.5	47
13	Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/Î²-lactam combinations. International Journal of Antimicrobial Agents, 2017, 49, 437-442.	2.5	3
14	The in vitro activity of ceftazidimeâ€“avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in SÃ£o Paulo, Brazil. Brazilian Journal of Infectious Diseases, 2017, 21, 569-573.	0.6	13
15	Modeling the Kinetics of the Permeation of Antibacterial Agents into Growing Bacteria and Its Interplay with Efflux. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	20
16	AmpC Î²-lactamase induction by avibactam and relebactam. Journal of Antimicrobial Chemotherapy, 2017, 72, 3342-3348.	3.0	20
17	The postantibiotic effect and post-Î²-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Letters in Applied Microbiology, 2016, 63, 96-102.	2.2	9
18	In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 3163-3169.	3.2	125

#	Article	IF	Citations
19	Structural and sequence analysis of class A Î²-lactamases with respect to avibactam inhibition: impact of Î©-loop variations. Journal of Antimicrobial Chemotherapy, 2016, 71, 2848-2855.	3.0	26
20	In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 4743-4749.	3.2	132
21	Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 368-375.	3.2	87
22	Inhibitory activity of avibactam against selected Î²-lactamases expressed in an isogenic Escherichia coli strain. Diagnostic Microbiology and Infectious Disease, 2016, 86, 83-85.	1.8	8
23	Î²-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1328-1335.	3.2	24
24	In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. International Journal of Antimicrobial Agents, 2016, 47, 235-242.	2.5	30
25	Role of the Outer Membrane and Porins in Susceptibility of Î²-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2016, 60, 1349-1359.	3.2	97
26	Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy, 2016, 60, 752-756.	3.2	63
27	Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice. Antimicrobial Agents and Chemotherapy, 2015, 59, 2299-2304.	3.2	43
28	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2015, 82, 65-69.	1.8	38
29	In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase. Antimicrobial Agents and Chemotherapy, 2015, 59, 5324-5330.	3.2	142
30	In Vitro Susceptibility of Characterized Î²-Lactamase-Producing Strains Tested with Avibactam Combinations. Antimicrobial Agents and Chemotherapy, 2015, 59, 1789-1793.	3.2	114
31	In Vitro Activity of Ceftazidime-Avibactam Combination in In Vitro Checkerboard Assays. Antimicrobial Agents and Chemotherapy, 2015, 59, 1138-1144.	3.2	37
32	In Vivo Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 6913-6919.	3.2	42
33	Activities of Ceftazidime and Avibactam against Î²-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 3366-3372.	3.2	74
34	Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. Journal of Chemotherapy, 2014, 26, 333-338.	1.5	45
35	In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China. Antimicrobial Agents and Chemotherapy, 2014, 58, 1774-1778.	3.2	81
36	Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against Î²-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2014, 58, 5297-5305.	3.2	101

#	Article	IF	Citations
37	Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 1365-1371.	3.2	55
38	Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2012, 56, 6137-6146.	3.2	107
39	Permeability of Bacteria to Antibacterial Agents. , 2012, , 849-879.		8
40	Towards a fundamental understanding of the MIC of Î²-lactam antibiotics. Journal of Antimicrobial Chemotherapy, 1988, 22, 275-283.	3.0	13
41	Estimation of the permeability parameter (C) for the flux of a charged molecule across the Gram-negative bacterial outer membrane. Biochemical Society Transactions, 1985, 13, 697-698.	3.4	8